ATOWW (Atossa Therapeutics) Net Issuance of Debt : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Atossa Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Atossa Therapeutics's net issuance of debt for the three months ended in Dec. 2024 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Atossa Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Atossa Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Net Issuance of Debt Chart

Atossa Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Issuance of Debt

Get a 7-Day Free Trial

Atossa Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Atossa Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Atossa Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (OTCPK:ATOWW) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.